Mizuho Securities analyst Difei Yang reiterated a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $14.00. The company’s shares closed last Thursday at $5.74.
According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.8% and a 37.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Magenta Therapeutics, and Akebia Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals with a $14.00 average price target.
See today’s analyst top recommended stocks >>
Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $9.45 million and GAAP net loss of $16 million. In comparison, last year the company earned revenue of $313K and had a GAAP net loss of $32.84 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
